A rumor regarding Day One Biopharmaceuticals (DAWN) was highlighted again in Ben Harrington’s M&A-focused Betaville blog, contacts tell The Fly. Day One shares are up $1.09, or 11%, to $11.12 in afternoon trading.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Day One Biopharmaceuticals: Ojemda Uptake, Strong 2026 Guidance, and Underappreciated Emi‑Le Catalyst Support Buy Rating
- Day One Highlights OJEMDA’s EMA Progress, Updates Strategy
- Day One Biopharmaceuticals price target raised to $30 from $29 at Wedbush
- Day One Biopharmaceuticals: Durable OJEMDA Launch, De‑Risked Revenue Outlook, and Clinical Catalysts Underpin Buy Rating and $17 Price Target
- Day One price target lowered to $22 from $25 at H.C. Wainwright